Navigation Links
CV Therapeutics' Anti-Ischemic Agent Ranexa(R) Significantly Reduces HbA1c and Other Markers of Diabetes in MERLIN TIMI-36
Date:11/6/2007

s compared to placebo.

"The results of the MERLIN TIMI-36 study confirm that ranolazine is a safe and effective anti-ischemic drug that also has favorable effects on arrhythmia and HbA1c," Morrow said. "The reduction in HbA1c observed with ranolazine in the MERLIN TIMI-36 study is especially striking because the effects were observed on top of multiple other anti-diabetic drugs used as part of standard therapy."

In accordance with a special protocol assessment agreement between the U.S. Food and Drug Administration (FDA) and CV Therapeutics, the Company believes that data from the MERLIN TIMI-36 study could support expansion of the existing Ranexa indication to first line angina. In September 2007, the Company submitted a supplemental new drug application to the FDA seeking a new indication for first line angina and a significant reduction in cautionary language.

Ranexa is currently indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs, and should be used in combination with amlodipine, beta-blockers or nitrates.

Study Design

MERLIN TIMI-36 (Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary Syndromes) was a multi-national, double-blind, randomized, placebo-controlled, parallel-group clinical trial designed to evaluate the efficacy and safety of Ranexa during acute and long-term treatment in 6,560 patients (3,279 received ranolazine, 3,281 received placebo) with non-ST elevation ACS treated with standard therapy.

Within 48 hours of the onset of angina due to ACS, eligible hospitalized patients were enrolled in the study and randomized to receive intravenous Ranexa or placebo, followed by long-term outpatient treatment with Ranexa extended-release tablets or placebo. All patients also received standard therapy during both hospital-based and outpatient treatment. The doses of Ranexa extended-release tablets used in MERL
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... , May 01, 2015 Research and Markets ... "Asian Dermatology Devices Market by Type, by End User - ... The Asian Dermatology Devices market is estimated to grow at ... China holds a larger share in the Dermatology ... Japan . The Asian Dermatology Devices market holds a ...
(Date:5/1/2015)... At the American Association of Neurological Surgeons (AANS) Annual ... , Elekta will highlight Leksell Gamma Knife® Registry ... enormous amount of data – generated by thousands of ... advance clinical research and further optimize patient care. ... allows practitioners to store, retrieve, and analyze Gamma Knife ...
(Date:5/1/2015)... Pharmacyclics, Inc. (the "Company") (NASDAQ: PCYC ) today ... 2015, as well as general business updates. Due to ... be held. Key Highlights , Total ... to $206 million from $119 million for the quarter ... (ibrutinib) net product revenue of $247 million was ...
Breaking Medicine Technology:Asian Dermatology Devices (Treatment & Diagnostic) Market by Type, by End User - Forecast to 2019 2Asian Dermatology Devices (Treatment & Diagnostic) Market by Type, by End User - Forecast to 2019 3Elekta to showcase Leksell Gamma Knife Registry at AANS Annual Meeting 2Elekta to showcase Leksell Gamma Knife Registry at AANS Annual Meeting 3Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 2Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 3Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 4Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 5Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 6Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 7Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 8Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 9Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 10Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 11Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 12Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 13Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 14Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 15Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 16Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 17Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 18Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 19Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 20Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 21Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 22Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 23Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 24Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 25Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 26Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 27Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 28Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 29Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 30Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 31Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 32
... from cutting-edge treatment, CHARLESTON, S.C., April 30 ... Charleston was diagnosed with craniosynostosis, a,condition that leads ... causing problems with normal brain and skull growth., ... Amelia,s skull was,growing in an asymmetrical fashion, a ...
... WILMINGTON, Del., April 30 AstraZeneca (NYSE:,AZN) today ... Application,(sNDA) to the U.S. Food and Drug Administration ... (budesonide/formoterol fumarate dihydrate),Inhalation Aerosol for the treatment of ... currently approved for the long-term,maintenance treatment of asthma ...
Cached Medicine Technology:STARscanner, STARband Cranial Helmets Making a Difference in the Lives of Children 2STARscanner, STARband Cranial Helmets Making a Difference in the Lives of Children 3AstraZeneca Submits an sNDA for SYMBICORT(R) for COPD Indication 2AstraZeneca Submits an sNDA for SYMBICORT(R) for COPD Indication 3AstraZeneca Submits an sNDA for SYMBICORT(R) for COPD Indication 4AstraZeneca Submits an sNDA for SYMBICORT(R) for COPD Indication 5
(Date:5/4/2015)... May 04, 2015 Today, Cireson reveals ... Cireson Platform to strengthen core service & ... a choice to consume Microsoft System Center and Cireson ... premise , Company transitioning from a direct ... Continuous innovation with expanding new solutions for password ...
(Date:5/3/2015)... Association 2015 Meeting & Tradeshow (PRWEB) May 03, ... full-service telemedicine and mobile health services provider today ... health services for chronic disease management, in the ... remote patient monitoring of a variety of chronic ... diabetes, COPD, hypertension and other chronic illnesses. , ...
(Date:5/3/2015)... ST. LOUIS, Missouri (PRWEB) May 03, 2015 ... in international business that will directly impact your ... (EMIB), is designed for dynamic leaders in multinational ... a multinational company. In a changing global landscape, ... business negotiations and relationships. The EMIB program develops ...
(Date:5/2/2015)... one of only 30 Illinois companies to be a ... Recognition Program (SHARP) certification, Essentra Specialty Tapes ... of Labor to host this special event. The ... Occupational Safety and Health Administration’s (“OSHA”) Onsite Consultation Program ... exceed all of the necessary regulations and standards, thanks ...
(Date:5/2/2015)... 02, 2015 It’s a pattern that ... disaster strikes anywhere on this planet, cyber scammers will ... and compassion for their own personal gain. And ... Readiness Team) issued an alert titled “Nepal Earthquake ... scams citing the earthquake in Nepal. The scam emails ...
Breaking Medicine News(10 mins):Health News:Cireson Unveils New Microsoft Cloud & System Center Strategy 2Health News:Cireson Unveils New Microsoft Cloud & System Center Strategy 3Health News:Cireson Unveils New Microsoft Cloud & System Center Strategy 4Health News:vitaphone e-health solutions U.S. Announces VITA Health Services for Remote Chronic Disease Management 2Health News:vitaphone e-health solutions U.S. Announces VITA Health Services for Remote Chronic Disease Management 3Health News:The Saint Louis University's Master of International Business Is Now Enrolling For Fall 2015 2Health News:Essentra Specialty Tapes is Selected to Host Gov. Rauner and the Workers' Memorial Day Celebration 2Health News:Essentra Specialty Tapes is Selected to Host Gov. Rauner and the Workers' Memorial Day Celebration 3Health News:Cyber Aftershocks from Nepal’s Earthquake Can Cripple Businesses Right Here at Home 2Health News:Cyber Aftershocks from Nepal’s Earthquake Can Cripple Businesses Right Here at Home 3Health News:Cyber Aftershocks from Nepal’s Earthquake Can Cripple Businesses Right Here at Home 4
... men with low-risk prostate cancer than the common method ... a research// team at the University of Michigan in ... conducted by lead researcher Dr. John T. Wei and ... the National Cancer Institute. Their studies have revealed that ...
... his electorate of Warringah this morning, AMA President, Dr ... already shrinking GP workforce will retire over the next ... week's Medical Journal of Australia confirming that general practice ... graduates, the challenge is how to support those staying ...
... find the response time of ambulance services for emergency calls ... details for how they responded to the most serious life-threatening ... target saying 75 per cent of such 'Category A' calls ... by the Information Center for Health and Social Care from ...
... grow rapidly unless eight countries in the region, especially ... measures, according to a new World Bank report. ... in South Asia, with the epidemic increasingly driven by ... said the report presented at the 16th International AIDS ...
... children from Isiolo District in Northern Kenya have died at ... a tropical infection caused by protozoa// of the genus Leishmania, ... ,It spreads to people through the bite of the sand ... in the victim’s body, invading the immune system. However, not ...
... a good alternative for identifying risks for kidney disease, cardiovascular ... by a researcher at the San Francisco VA Medical Center, ... is incapable of picking up chronic health risks among the ... others at risk for kidney disease, this is an important ...
Cached Medicine News:Health News:Watchful Waiting Effective for Low Risk Prostate Cancer 2Health News:Keep Australia's GP Workforce Numbers Healthy, AMA Urges 2Health News:Incorrect Recording Of Response Time By Six Ambulance Trusts 2Health News:India Urged to Take Stringent Measures to Combat AIDS 2Health News:India Urged to Take Stringent Measures to Combat AIDS 3Health News:Cystatin C Test- A Reliable Test to Detect Chronic Health Risks 2Health News:Cystatin C Test- A Reliable Test to Detect Chronic Health Risks 3
... Maximum Xtra, and Maximum ACT introducers ... and specialty hemostasis introducers in the ... premier hemostasis introducers for use in ... angiography, angioplasty, stenting, atherectomy, temporary pacing, ...
... provide outstanding insertion performance, with ... high kink resistance and minimal ... sheath cannula provides optimal strength ... an extra strong dilator to ...
Bx VELOCITY Coronary Stent with HEPACOAT...
A steerable diagnostic catheter with optimal maneuverability...
Medicine Products: